Chimerix crushed on Phase III brincidofovir miss

Chimerix Inc. (NASDAQ:CMRX) dropped $28.95 (81%) to $6.62 on Monday after brincidofovir ( CMX001) missed its primary endpoint in the Phase III SUPPRESS trial. The candidate failed to prevent clinically significant cytomegalovirus (CMV) infection through week 24 in hematopoietic stem cell transplant (HSCT) recipients. Chimerix had planned to use data from SUPPRESS to support accelerated approval of brincidofovir in the indication.

During the study's 14-week treatment period, fewer patients in the brincidofovir arm had CMV infections compared to the control arm, consistent with Phase II results. However, during the off-treatment period from week 14 to week 24, there was an increase in CMV infections and a non-statistically significant increase in mortality in the brincidofovir arm vs. control (see BioCentury Extra, Feb. 6, 2012). ...